- CureToday.com
- OncLive.com
- TargetedOnc.com
- CancerNetwork.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Amy K. Erbe, PhD | Authors
Articles
Marker May Predict Immunotherapy Benefit in High-Risk Neuroblastoma
April 08, 2017
This video examines how a specific combination of KIR/KIR-ligand genotypes in high-risk neuroblastoma patients may be predictive of outcomes when adding dinutuximab to isotretinoin.